Qualcomm to Acquire Modular for ~$4 Billion to Challenge NVIDIA in AI Software
The deal strengthens Qualcomm’s push into data centers and challenges NVIDIA’s CUDA dominance.
Already have an account? Sign in.
The deal strengthens Qualcomm’s push into data centers and challenges NVIDIA’s CUDA dominance.
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.
Board forms special committee to evaluate the offer.